• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.

作者信息

McKenney Jim

机构信息

National Clinical Research, Richmond, Virginia 23294, USA.

出版信息

Am J Cardiol. 2002 Nov 20;90(10B):8K-20K. doi: 10.1016/s0002-9149(02)02967-3.

DOI:10.1016/s0002-9149(02)02967-3
PMID:12467936
Abstract

Lowering elevated low-density lipoprotein (LDL) cholesterol is a key management principle in reducing the risk of coronary artery disease (CAD). An aggressive approach to CAD risk reduction requires multiple therapeutic strategies, as no single approach is likely to succeed independently. The use of combination therapy for elevated LDL cholesterol is effective for CAD risk reduction. In fact, the majority of patients with CAD are unlikely to achieve their treatment goals with monotherapy. This article reviews the use of combination therapy for the management of elevated LDL cholesterol, highlighting important therapy considerations.

摘要

相似文献

1
Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.
Am J Cardiol. 2002 Nov 20;90(10B):8K-20K. doi: 10.1016/s0002-9149(02)02967-3.
2
Managing dyslipidemia in the high-risk patient.高危患者血脂异常的管理。
Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. doi: 10.1016/s0002-9149(02)02229-4.
3
The rationale for combination therapy.联合治疗的基本原理。
Am J Cardiol. 2002 Nov 20;90(10B):2K-7K. doi: 10.1016/s0002-9149(02)02966-1.
4
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
Am J Cardiol. 2002 Nov 20;90(10B):30K-43K. doi: 10.1016/s0002-9149(02)02971-5.
5
Combination therapy for combined dyslipidemia.混合性血脂异常的联合治疗。
Am J Cardiol. 2002 Nov 20;90(10B):21K-29K. doi: 10.1016/s0002-9149(02)02968-5.
6
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.低密度脂蛋白胆固醇水平为5:联合药物治疗低密度脂蛋白胆固醇的益处与风险
Prev Cardiol. 2010 Spring;13(2):69-71. doi: 10.1111/j.1751-7141.2009.00052.x.
7
Use of combination therapy for dyslipidemia: a lipid clinic approach.血脂异常联合治疗的应用:脂质门诊治疗方法
Am J Cardiol. 2002 Nov 20;90(10B):44K-49K. doi: 10.1016/s0002-9149(02)02969-7.
8
Combination therapy for dyslipidemia: safety and regulatory considerations.血脂异常的联合治疗:安全性及监管考量
Am J Cardiol. 2002 Nov 20;90(10B):50K-60K. doi: 10.1016/s0002-9149(02)02970-3.
9
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.近期ATP III指南的治疗意义及联合治疗在全面血脂异常管理中的重要作用。
Curr Opin Cardiol. 2003 Jul;18(4):278-85. doi: 10.1097/00001573-200307000-00007.
10
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.使用他汀类药物与烟酸联合疗法针对与低密度脂蛋白和高密度脂蛋白相关的心血管风险。
J Cardiovasc Risk. 2002 Dec;9(6):339-47. doi: 10.1097/01.hjr.0000044518.34172.72.

引用本文的文献

1
Optimal lipid modification: the rationale for combination therapy.最佳脂质修饰:联合治疗的基本原理。
Vasc Health Risk Manag. 2005;1(4):317-31. doi: 10.2147/vhrm.2005.1.4.317.